Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HRMY NASDAQ:ITMR NASDAQ:PGNY NASDAQ:QDEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$32.39-3.1%$35.65$26.47▼$41.61$1.92B0.84627,965 shs809,622 shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/APGNYProgyny$22.51-2.8%$23.05$13.39▼$26.76$1.99B1.33878,929 shs801,637 shsQDELQuidelOrtho$28.57-4.6%$26.94$22.05▼$49.45$2.03B0.141.08 million shs1.15 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences-3.08%-10.00%-11.67%-1.76%-13.12%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%PGNYProgyny-2.85%-0.18%-2.39%+7.04%-1.70%QDELQuidelOrtho-4.58%-0.38%+5.50%-1.14%-36.30%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHRMYHarmony Biosciences$32.39-3.1%$35.65$26.47▼$41.61$1.92B0.84627,965 shs809,622 shsITMRItamar Medical$30.87$30.75$16.36▼$30.91$497.25M0.7390,796 shsN/APGNYProgyny$22.51-2.8%$23.05$13.39▼$26.76$1.99B1.33878,929 shs801,637 shsQDELQuidelOrtho$28.57-4.6%$26.94$22.05▼$49.45$2.03B0.141.08 million shs1.15 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHRMYHarmony Biosciences-3.08%-10.00%-11.67%-1.76%-13.12%ITMRItamar Medical0.00%0.00%0.00%0.00%0.00%PGNYProgyny-2.85%-0.18%-2.39%+7.04%-1.70%QDELQuidelOrtho-4.58%-0.38%+5.50%-1.14%-36.30%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHRMYHarmony Biosciences 3.00Buy$51.0057.46% UpsideITMRItamar Medical 0.00N/AN/AN/APGNYProgyny 2.73Moderate Buy$25.3012.39% UpsideQDELQuidelOrtho 2.33Hold$39.2037.21% UpsideCurrent Analyst Ratings BreakdownLatest ITMR, PGNY, HRMY, and QDEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025PGNYProgynyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$23.00 ➝ $25.008/20/2025PGNYProgynyCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$21.00 ➝ $23.008/8/2025PGNYProgynyRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$28.008/8/2025PGNYProgynyCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$26.00 ➝ $28.008/7/2025QDELQuidelOrthoUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$29.00 ➝ $26.008/6/2025QDELQuidelOrthoCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$50.00 ➝ $40.007/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$48.007/17/2025PGNYProgynyTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetHold$24.00 ➝ $27.007/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$33.007/8/2025PGNYProgynyLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHRMYHarmony Biosciences$772.53M2.41$2.86 per share11.34$11.56 per share2.80ITMRItamar Medical$41.03M12.12N/AN/AN/A∞PGNYProgyny$1.24B1.56$0.34 per share67.14$4.96 per share4.54QDELQuidelOrtho$2.78B0.70$34.01 per share0.84$44.38 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHRMYHarmony Biosciences$145.49M$3.1010.4510.410.3923.44%26.34%17.71%11/4/2025 (Estimated)ITMRItamar MedicalN/A-$1.35N/AN/AN/AN/AN/AN/AN/APGNYProgyny$54.34M$0.5938.1534.631.894.28%10.69%7.12%11/11/2025 (Estimated)QDELQuidelOrtho-$2.05B-$6.54N/A8.90N/A-16.10%5.29%2.43%11/6/2025 (Estimated)Latest ITMR, PGNY, HRMY, and QDEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025PGNYProgyny$0.42$0.19-$0.23$0.19$315.70 million$332.87 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million8/5/2025Q2 2025QDELQuidelOrtho$0.0122$0.12+$0.1078-$3.77$612.36 million$613.90 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHRMYHarmony BiosciencesN/AN/AN/AN/AN/AITMRItamar MedicalN/AN/AN/AN/AN/APGNYProgynyN/AN/AN/AN/AN/AQDELQuidelOrthoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHRMYHarmony Biosciences0.203.843.80ITMRItamar MedicalN/AN/AN/APGNYProgynyN/A2.702.70QDELQuidelOrtho0.741.120.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHRMYHarmony Biosciences86.23%ITMRItamar Medical42.19%PGNYProgyny94.93%QDELQuidelOrtho99.00%Insider OwnershipCompanyInsider OwnershipHRMYHarmony Biosciences23.60%ITMRItamar MedicalN/APGNYProgyny9.40%QDELQuidelOrtho0.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableITMRItamar Medical25716.11 millionN/ANot OptionablePGNYProgyny31085.98 million77.90 millionOptionableQDELQuidelOrtho6,60067.90 million67.36 millionOptionableITMR, PGNY, HRMY, and QDEL HeadlinesRecent News About These CompaniesRBC Capital Raises PT on QuidelOrtho Corporation From $60 to $62, Keeps Buy RatingSeptember 10 at 2:10 AM | insidermonkey.comFocus Partners Advisor Solutions LLC Invests $380,000 in QuidelOrtho Corporation $QDELSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation (NASDAQ:QDEL) Receives Consensus Recommendation of "Hold" from BrokeragesSeptember 8, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Stock Holdings Raised by AQR Capital Management LLCSeptember 7, 2025 | marketbeat.comQuidelOrtho Corporation (NASDAQ:QDEL) Given Consensus Recommendation of "Hold" by AnalystsSeptember 7, 2025 | americanbankingnews.comQuidelOrtho Corporation $QDEL Shares Sold by Magnetar Financial LLCSeptember 5, 2025 | marketbeat.comQUIDELORTHO ALERT: Bragar Eagel & Squire, P.C. is Investigating QuidelOrtho Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmSeptember 4, 2025 | globenewswire.com67,619 Shares in QuidelOrtho Corporation $QDEL Purchased by Birchview Capital LPSeptember 4, 2025 | marketbeat.comHBK Investments L P Has $16.88 Million Stock Holdings in QuidelOrtho Corporation $QDELSeptember 3, 2025 | marketbeat.comQuidelOrtho Corporation $QDEL Holdings Increased by Paradigm Capital Management Inc. NYSeptember 2, 2025 | marketbeat.comIeq Capital LLC Increases Holdings in QuidelOrtho Corporation $QDELAugust 31, 2025 | marketbeat.comRussell Investments Group Ltd. Has $1.42 Million Holdings in QuidelOrtho Corporation $QDELAugust 30, 2025 | marketbeat.comQuidelOrtho to Participate in the Baird 2025 Global Healthcare ConferenceAugust 28, 2025 | prnewswire.comJump Financial LLC Boosts Stake in QuidelOrtho Corporation $QDELAugust 28, 2025 | marketbeat.com221,658 Shares in QuidelOrtho Corporation $QDEL Acquired by Nuveen LLCAugust 27, 2025 | marketbeat.comQuidelOrtho Completes Major Debt Refinancing TransactionAugust 23, 2025 | theglobeandmail.comT. Rowe Price Investment Management Inc. Has $400.31 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 23, 2025 | marketbeat.comQuidelOrtho Corporation: QuidelOrtho Completes Debt RefinancingAugust 22, 2025 | finanznachrichten.deAmerican Century Companies Inc. Increases Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Has $28.99 Million Stock Holdings in QuidelOrtho Corporation $QDELAugust 22, 2025 | marketbeat.comQuidelOrtho Completes Debt Refinancing | QDEL Stock NewsAugust 21, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeITMR, PGNY, HRMY, and QDEL Company DescriptionsHarmony Biosciences NASDAQ:HRMY$32.39 -1.03 (-3.08%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$33.10 +0.70 (+2.18%) As of 09/12/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.Itamar Medical NASDAQ:ITMRItamar Medical Ltd. engages in the research, development, marketing, selling, and leasing of non-invasive medical devices based on peripheral arterial tone signals. It develops and markets two products, namely, WatchPAT and EndoPAT. The WatchPAT diagnoses sleep apnea, which has been proven to be a substantial risk factor in cardiac disease. The EndoPAT diagnoses endothelial malfunction, which is a proven predictor of cardiovascular disease. The company was founded by Yaron Giora , Martin Gerstel, Peretz Lavie, and Daniel Gur on January 15, 1997 and is headquartered in Caesarea, Israel.Progyny NASDAQ:PGNY$22.51 -0.66 (-2.85%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$22.52 +0.00 (+0.02%) As of 09/12/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.QuidelOrtho NASDAQ:QDEL$28.57 -1.37 (-4.58%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$29.14 +0.57 (+1.98%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
